ProfileGDS5678 / 1438021_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 70% 70% 71% 70% 71% 71% 75% 72% 70% 71% 70% 70% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4226871
GSM967853U87-EV human glioblastoma xenograft - Control 24.4237270
GSM967854U87-EV human glioblastoma xenograft - Control 34.3773770
GSM967855U87-EV human glioblastoma xenograft - Control 44.6135871
GSM967856U87-EV human glioblastoma xenograft - Control 54.3222570
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4334671
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4152471
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.93475
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5976672
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4101870
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4093971
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.42670
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3617570
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4169471